睡眠模式与银屑病疾病风险:遗传易感性与代谢组学
该前瞻性队列研究纳入英国生物银行399 912名无银屑病疾病(PsD)参与者,随访14.7年发现4001例新发PsD。不良睡眠模式显著增加PsD风险,在高遗传易感性人群中尤为明显,且该关联部分由炎症和代谢生物标志物介导。
要点
- 不良睡眠模式增加银屑病疾病风险,高遗传风险者风险更高。
- 低遗传风险且高睡眠评分者PsD风险最低(HR 0.35)。
- 糖蛋白乙酰化等代谢物部分介导睡眠与PsD的关联。
核心结论
- 不良睡眠模式显著增加银屑病疾病风险,尤其在高遗传易感性人群中。
- 该关联部分由炎症和代谢生物标志物介导,优化睡眠是可改变的生活方式因素。
研究设计与样本
- 前瞻性队列研究,纳入英国生物银行399 912名无PsD参与者。
- 采用Cox比例风险模型分析睡眠模式与PsD风险的关联。
- 计算多基因风险评分(PRS)并评估与睡眠模式的交互作用。
- 进行中介分析识别血清代谢物的潜在中介效应。
主要发现
- 平均随访14.7年,新发PsD 4001例。
- 低PRS且高睡眠评分者相比高PRS且低睡眠评分者PsD风险最低(HR 0.35,95%CI 0.28-0.43)。
- 初始未检测到PRS与睡眠评分的显著交互作用(P=0.08)。
- 采用中位数二分PRS后,发现乘性交互(P=0.003)和加性交互(RERI 0.36,95%CI 0.17-0.55;P<0.001)。
- 糖蛋白乙酰化、多不饱和脂肪酸与单不饱和脂肪酸比值及碱性磷酸酶部分介导睡眠-PsD关联。
临床怎么用
- 改善睡眠模式可能有助于降低银屑病疾病风险,尤其在高遗传风险人群中。
- 睡眠优化可作为可改变的生活方式因素纳入PsD风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The longitudinal impact of comprehensive sleep patterns on incident psoriatic disease (PsD) and the potential mediating effects are unclear. OBJECTIVES: To investigate the associations of sleep patterns with PsD risk, alongside the role of genetic predisposition and the potential mediating effects of serum metabolites. METHODS: This prospective cohort study included 399 912 participants without PsD registered in UK Biobank. Cox proportional hazard models were used to examine the association between sleep patterns, genetic risk of PsD and the overall risk of PsD. Cross-product interaction terms between polygenic risk score (PRS) categories and sleep patterns were incorporated into the fully adjusted models, and the relative excess risk due to interaction (RERI) was calculated to examine additive interaction. Mediation analyses were used to identify specific metabolites as potential mediators of PsD. RESULTS: During a mean follow-up of 14.7 years, 4001 new cases of PsD were identified. Compared with those with high PRS and low sleep scores, participants with low PRS and high sleep scores had the lowest risk of PsD [hazard ratio 0.35, 95% confidence interval (CI) 0.28-0.43]. Although no significant interaction between PRS and sleep score was initially detected (P = 0.08), subsequent analyses using a median-dichotomized PRS revealed multiplicative (P = 0.003) and additive interactions (RERI 0.36, 95% CI 0.17-0.55; P < 0.001). Mediation analyses identified glycoprotein acetylation, the ratio of polyunsaturated fatty acids to monounsaturated fatty acids and alkaline phosphatase as partial mediators of the sleep-PsD association. CONCLUSIONS: Unfavourable sleep patterns significantly increase the risk of PsD, especially in people with a high genetic predisposition to PsD. This association is partially mediated by inflammatory and metabolic biomarkers, highlighting sleep optimization as a modifiable lifestyle factor for mitigating PsD risk. Psoriatic disease is a long-term disease caused by immune system overactivity. It includes psoriasis and psoriatic arthritis. Psoriasis affects the skin, causing raised patches of scaly skin. About 1 in 5 people with psoriasis will also develop psoriatic arthritis. This can cause pain and joint damage. Psoriatic disease can have a negative impact on the quality of a person’s sleep. We carried out a large study to examine how sleep patterns affect the development of psoriatic disease in the general population. To do this, we used data from a group of participants registered in a large database. Using this information, we investigated how different factors affect people’s health. Our findings suggest that unhealthy sleep patterns could increase the risk of this disease. This is especially true in people who may be genetically more prone to developing it. Certain molecules were also identified as being important. These molecules can help researchers identify links between diet or environmental factors and people’s health. We identified several molecules partly linking poor sleep and psoriatic disease. Our findings highlight the role of sleep as a modifiable lifestyle factor. Improving sleep patterns may help reduce the risk of psoriatic disease.
引用
- Guo Z, Luo Z, Zhang S, et al. Sleep patterns and the risk of psoriatic disease: genetic predisposition and metabonomics. Br J Dermatol. 2026. PMID: 41240371. doi:10.1093/bjd/ljaf463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。